AQIX
LIVE

Serial Number

79134000

Owner

Aqix Limited

Attorney

Tracy Deutmeyer

Filing Date

May 3, 2013

Add to watchlist:

No watchlists yet
View on USPTO

AQIX Trademark

Serial Number: 79134000 • Registration: 4473215

AQIX is a trademark filed by Aqix Limited on May 3, 2013. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Aqix Limited

London BioScience Innovation Centre,

Entity Type: 99

Trademark Details

Filing Date

May 3, 2013

Registration Date

January 28, 2014

Published for Opposition

November 12, 2013

Cancellation Date

March 6, 2026

Goods & Services

[Laboratory services for analytical testing; laboratory services relating to the researching of pharmaceuticals and solutions for medical and surgical use and solutions for supporting human and animal cells, tissue and organs, solutions for use and application in infusion therapy, organ transplant perfusion and cell or tissue bio-specimen collection and preservation, solutions for storing human and animal organs, tissues and cells, solutions for replacing, synthesizing, diluting, rehydrating and expanding human and animal blood, intravascular and extravascular fluids, solutions for testing drugs on human and animal cells, tissue and organs, media for stem cell and DNA research and therapy; scientific research; medical transplant research services; medical research; scientific analysis of human tissue and human serum for medical research; stem cell and DNA scientific and medical research services; chemical research and development services; chemical, medical and scientific testing and analysis for medical research purposes; testing of pharmaceutical solutions for medical research purposes; quality control services for others; clinical medical and scientific research; conducting of clinical trials for others; design and development of new technology and products for other uses in medical and veterinary fields;] Information, advisory and consultancy services relating to [ all of the aforesaid] * laboratory services for analytical testing and to scientific research *

Solutions for medical and clinical use in supporting human and animal cells, tissue and organs; solutions for medical and clinical use and application in infusion therapy, organ transplant perfusion and cell or tissue bio-specimen collection and preservation, such preservation being to preserve stem cells and their therapeutic applications; solutions for intravenous use for medical, surgical and veterinary purposes; cultures for growing cells, bacteria [ and viruses ] for medical and clinical purposes; solutions for medical and clinical use for replacing, synthesizing, diluting, rehydrating and expanding human and animal blood, intravascular and extravascular fluids; solutions for medical and clinical use for cell, organ and tissue preservation and the creation of a homeostasis to regulate the environment of cells, organs and tissues; solutions for medical and clinical use for testing drugs on ex vivo perfused human and animal cells, tissue and organs; cell, bacteria and virus growth media, storage media and transportation media for medical or clinical use for stem cell and DNA research and therapy; pharmaceutical transfer agents or components for pharmaceuticals in the form of solutions for medical use for application in infusion therapy, organ transplant perfusion and cell or tissue bio-specimen collection and preservation; tissue regenerative pharmaceutical preparations and solutions; stem cells for medical and veterinary purposes; clinical diagnostic preparations for medical or veterinary use; clinical medical reagents; medical diagnostic reagents for proteomic, genomic and metabolomic analysis of tissues, cells, bacteria and viruses and testing the stability of homeostasis within organs, tissues, cells, bacteria and viruses for medical use; * none of the aforesaid * being or * relating to ready-made pharmaceuticals * substances, preparations, compositions or solutions * and none of the aforesaid * being * for use in connection with the * detection or * treatment of herpes and related viral diseases *, or for use with tissue or organs infected by herpes or related viral diseases *

Chemicals for use in scientific analysis; chemicals for scientific purposes, namely, making pharmaceutical and veterinary preparations, being media for storing organs, tissue and cells; cell, bacteria and virus growth media for use with cell, bacterial and viral cultures in scientific research

Filing History

CANCELLED SECTION 71
Mar 6, 2026 C71T
INTERNATIONAL REGISTRATION RENEWED
Oct 12, 2023 RNWL
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Jan 28, 2023 REM4
NOTICE OF PARTIAL CANCELLATION SEC. 7 SURRENDER EMAILED
Feb 5, 2021 NCP7
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Feb 4, 2021 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Feb 4, 2021 C75A
CANCELLED SEC. 7 - PARTIAL
Feb 4, 2021 C7P.
NEW REPRESENTATIVE AT IB RECEIVED
Dec 18, 2020 NREP
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 25, 2020 APRE
TEAS SECTION 71 & 15 RECEIVED
Jul 28, 2020 ES75
TEAS SECTION 7 REQUEST RECEIVED
Jul 28, 2020 ES7R
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jan 28, 2019 REM3
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Apr 13, 2018 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Apr 10, 2018 INPR
CORRECTION UNDER SECTION 7 - PROCESSED
Aug 10, 2017 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Aug 10, 2017 APRE
LIMITATION FROM THE IB EXAMINED AND ENTERED
Aug 10, 2017 LIME
LIMITATION OF GOODS RECEIVED FROM IB
Jun 16, 2017 LIMG
CHANGE OF NAME/ADDRESS REC'D FROM IB
Oct 27, 2016 ADCH
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Mar 12, 2016 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Jan 7, 2016 INPR
CORRECTION UNDER SECTION 7 - PROCESSED
May 7, 2015 COC.
ASSIGNED TO PARALEGAL
May 7, 2015 PLGL
LIMITATION FROM THE IB EXAMINED AND ENTERED
May 7, 2015 LIME
LIMITATION OF GOODS RECEIVED FROM IB
May 1, 2015 LIMG
NEW REPRESENTATIVE AT IB RECEIVED
Nov 14, 2014 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 4, 2014 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 17, 2014 FICS
FINAL DISPOSITION PROCESSED
Jun 17, 2014 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 28, 2014 FICR
REGISTERED-PRINCIPAL REGISTER
Jan 28, 2014 R.PR
NEW REPRESENTATIVE AT IB RECEIVED
Dec 13, 2013 NREP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 12, 2013 NPUB
PUBLISHED FOR OPPOSITION
Nov 12, 2013 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 23, 2013 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 8, 2013 PREV
ASSIGNED TO LIE
Oct 7, 2013 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 25, 2013 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 24, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 24, 2013 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 24, 2013 TROA
REFUSAL PROCESSED BY IB
Sep 17, 2013 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 27, 2013 RFCS
REFUSAL PROCESSED BY MPU
Aug 27, 2013 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 25, 2013 RFCR
NON-FINAL ACTION WRITTEN
Aug 24, 2013 CNRT
ASSIGNED TO EXAMINER
Aug 22, 2013 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 13, 2013 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 9, 2013 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 8, 2013 REPR